Bristol-Myers Squibb Company
Lawrence Township, NJ Doing business as Bristol-Myers Squibb Bristol Myers Squibb Part of Bristol-Myers Squibb Company
- UEI
- UFGKB2B71N12
- CAGE
- 4K2D9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Bristol-Myers Squibb Company
Parent
L52ANKRJYPL2
- Bristol-Myers Squibb Company UFGKB2B71N12
-
Bristol-Myers Squibb Company
Parent
L52ANKRJYPL2
- SAM.gov registration date
- Physical address
- 3401 Princeton Pike, Lawrenceville, NJ 08648, USA
- Website
- bms.com
- Founded
- 1858
- Employees
- 10K-50K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Breyanzi injection | Veterans Integrated Service Network 9 | $364,139 | |
| Breyanzi injection MM8684 | Veterans Integrated Service Network 2 | $0 | |
| Abecma injection | Veterans Integrated Service Network 9 | $378,650 | |
| Pomalyst 4MG, camzyos 2.5 MG | Veterans Integrated Service Network 5 | $51,333 | |
| Pomalyst 2 MG, 3 MG,4 MG | Veterans Integrated Service Network 5 | $199,047 |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer headquartered in Lawrenceville, New Jersey, supplies specialized oncology and hematology pharmaceuticals to the Department of Veterans Affairs as a prime contractor on a full-and-open basis, with no small business set-aside designations across its federal footprint. The company competes predominantly through the GSA Federal Supply Schedule (Pharmaceuticals and Drugs, FSS-61-IB), a multiple-award IDIQ vehicle with a ceiling value of $12.278 billion extending through April 30, 2029.
Bristol-Myers Squibb's federal work centers on delivery orders and blanket purchase agreements for specialized cancer therapies and immunomodulatory agents. Representative delivery orders include BREYANZI (lisocabtagene maraleucel), a chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma, with individual orders ranging from approximately $310,900 to $670,085; ABECMA (idecabtagene vicleucel), a CAR T therapy for multiple myeloma and hematologic malignancies, with similar order values; and specialty oncology pharmaceuticals including REVLIMID (lenalidomide), POMALYST (pomalidomide), CAMZYOS (mavacamten), and Thalidomide. The company also holds two large single-award blanket purchase agreements: one for REVLIMID with a ceiling of $87.598 million through December 31, 2026, and another covering CAMZYOS, POMALYST, and THALOMID with a ceiling of $2.853 billion through January 15, 2027.
Customer concentration is heavily concentrated within the VA healthcare system. Of 111 total prime awards across all federal sources, the Veterans Integrated Service Network 9 (VISN 9) accounts for 48 awards with $13.3 million combined potential value, followed by VISN 5 with 32 awards and $1.5 million combined potential value. These two networks alone represent 72% of award count. By potential value, however, VISN 12 dominates with a single award of $23.83 billion (representing the parent FSS contract ceiling), followed by the National Acquisition Center with one award for $2.853 billion. The VA system accounts for substantially all federal business; the company serves twelve distinct federal customer agencies, but the VA dominates in both volume and dollars.
Recent activity has accelerated sharply. The company received one award in 2022, four in 2023, nineteen in 2024, twenty-four in 2025, and fifty-one through July 2026 — a sixfold increase year over year. Combined potential value across all 111 awards stands at $26.79 billion, though obligated dollars are only $19.1 million, reflecting the fact that most value sits in the large FSS ceiling and associated BPA ceilings rather than task-order commitments. Fifteen awards face ultimate completion inside the next twenty-four months, with combined potential value of $4.8 million facing recompete exposure.
Bristol-Myers Squibb operates entirely as a prime contractor (100% of awards); the source carries no subcontract relationships. Work is performed at the company's Lawrenceville, New Jersey facility and distributed through Memphis, Tennessee and other VA medical centers nationwide. The company's federal contracting footprint is concentrated on NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC codes for drugs and biologicals, with 109 of 111 awards coded to that category. The Federal Supply Schedule vehicle under which nearly all work flows carries delivery orders issued by multiple VISNs and supporting the VA's mission to supply advanced oncology and cell therapy treatments to eligible veterans, with ordering activity spanning fiscal years 2022 through 2026 and projected through April 2029.
Contract vehicles
Quick answers
What is Bristol-Myers Squibb Company's UEI?
Bristol-Myers Squibb Company's Unique Entity ID (UEI) in SAM.gov is UFGKB2B71N12.
What is Bristol-Myers Squibb Company's CAGE code?
Bristol-Myers Squibb Company's CAGE code is 4K2D9.
What is Bristol-Myers Squibb Company's primary NAICS code?
Bristol-Myers Squibb Company's primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Bristol-Myers Squibb Company located?
Bristol-Myers Squibb Company's physical address in SAM.gov is 3401 Princeton Pike, Lawrenceville, NJ 08648, USA.
Is Bristol-Myers Squibb Company registered in SAM.gov?
Yes. Bristol-Myers Squibb Company's SAM.gov registration is active through June 15, 2027.
Who is Bristol-Myers Squibb Company's parent company?
Bristol-Myers Squibb Company is part of Bristol-Myers Squibb Company.
Which contract vehicles does Bristol-Myers Squibb Company hold?
Bristol-Myers Squibb Company holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Bristol-Myers Squibb Company's most recent federal award?
Bristol-Myers Squibb Company's most recent federal contract award is Breyanzi injection (36C24926N0658), from Veterans Integrated Service Network 9, on September 11, 2026.
On GovTribe
See Bristol-Myers Squibb Company's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors